natgillin/translations-raw huggingface dataset:
The solution should be clear or slightly opalescent and colourless or pale yellow.
Raztopina mora biti bistra ali rahlo opalescentna in brezbarvna do rumenkasta.
The solution should be clear or slightly opalescent, colourless or pale yellow, and may contain small white or almost transparent particles of protein.
Raztopina mora biti bistra ali rahlo svetlikajoča, brezbarvna ali bledorumena in lahko vsebuje majhne bele ali skoraj prozorne delce beljakovine.
The solution should be clear or slightly opalescent, colourless or pale yellow, and may contain small white or almost transparent particles of protein.
Raztopina mora biti bistra do rahlo opalescentna, brezbarvna ali bledorumena ter lahko vsebuje majhne bele ali skoraj prosojne delce beljakovine.
The solution should be clear or slightly opalescent, i.e. it might be sparkling when held up to the light but must not contain any obvious particles.
Raztopina mora biti bistra ali nekoliko opalescentna, kar pomeni, da se lahko svetlika, če jo pogledate proti svetlobi, ne sme pa vsebovati očitnih delcev.
The solution should be clear or slightly opalescent, yellow to colourless, i.e. it might be sparkling when held up to the light but must not contain any obvious particles.
Raztopina mora biti bistra ali nekoliko opalescentna, rumena do brezbarvna, kar pomeni, da se lahko svetlika, če jo pogledate proti svetlobi, ne sme pa vsebovati vidnih delcev.
The solution should be clear or slightly opalescent.
Raztopina mora biti bistra ali nekoliko opalescentna.
The solution should be clear or slightly opalescent.
Raztopina mora biti prozorna ali rahlo opalescentna.
The solution should be clear to opalescent and free of visible particles.
Raztopina mora biti bistra do opalescentna in ne sme vsebovati vidnih delcev.
The solution should be clear to slightly opalescent, colourless or pale yellow and may contain small translucent or white particles of protein.
Raztopina mora biti bistra do rahlo opalescentna, brezbarvna ali bledo rumena ter lahko vsebuje majhne prosojne ali bele delce beljakovine.
The solution should be clear, colorless to slightly yellow, and free from visible particles.
Raztopina mora biti bistra, brezbarvna do rahlo rumenkasta in brez vidnih delcev.
The solution should be clear, colourless or pale yellow, with no lumps or flakes or particles.
Raztopina mora biti bistra, brezbarvna ali bledorumena in ne sme vsebovati kepic, kosmičev ali delcev.
The solution should be colourless or may have a slight brownish- yellow tint.
Raztopina mora biti brezbarvna ali rahlo rjavorumene barve.
The solution should be colourless or may have a slight brownish-yellow tint.
Raztopina mora biti brezbarvna ali pa ima lahko rahlo rjavorumen odtenek.
The solution should be colourless or may have a slight brownish-yellow tint.
Raztopina mora biti brezbarvna ali rahlo rjavorumene barve.
The solution should be discarded if particulate matter is visible.
Raztopino morate zavreči, če so v njej vidni delci.
The solution should be free of visible particles and clear to opalescent.
Raztopina mora biti bistra ali opalescentna in ne sme vsebovati vidnih delcev.
The solution should be free of visible particles and not cloudy.
Raztopina ne sme vsebovati vidnih delcev in ne sme biti motna.
The solution should be given using the measuring syringe provided in the package.
Raztopino se daje z merilno brizgo, ki je priložena pakiranju.
The solution should be inspected and any vial containing visible particulate matter should not be used.
Raztopino je treba pregledati, vial, ki vsebujejo vidne delce, pa se ne sme uporabiti.
The solution should be inspected visually prior to use.
Raztopino pred uporabo preglejte s prostim očesom.
The solution should be inspected visually prior to use.
Raztopino pred uporabo vizualno preglejte.
The solution should be mixed gently, and not be shaken.
Raztopino je treba nežno premešati in je ni dovoljeno stresati.
The solution should be shaken gently to mix well.
Raztopino nežno pretresite, da se zdravilo dobro premeša.
The solution should be used immediately after reconstitution.
Raztopino morate uporabiti takoj po pripravi.
The solution should be visually inspected for particulate matter and discolouration prior to administration.
Pred uporabo je treba raztopino vizualno pregledati zaradi morebitne prisotnosti delcev in opaznega obarvanja.
The solution should be visually inspected prior to use.
Raztopino pred injiciranjem preglejte.
The solution should be visually inspected prior to use.
Raztopino pred uporabo preglejte.
The solution should be visually inspected prior to use.
Raztopino zdravila Accofil morate pred uporabo vizualno pregledati.
The solution should be visually inspected prior to use.
Raztopino zdravila Grastofil morate pred uporabo vizualno pregledati.
The solution should be visually re-inspected for particulate matter and discolouration before administering.
Pred uporabo morate raztopino pregledati, da ne vsebuje delcev in da ni spremenila barve.
The solution should not be shaken.
Raztopine ne pretresajte.
The solution should not be used if discolored or cloudy, or if particulate matter is observed.
Če je raztopina obarvana, motna ali v njej opazite delce, je ne smete uporabiti.
The solution should not be used if discoloured or cloudy or if particulate matter is observed.
Če je raztopina motna, drugačne barve ali vsebuje trdne delce, se je ne sme uporabiti.
The solution should reconstitute in not more than 5 minutes.
Raztopina mora nastati v največ 5 minutah.
The solution will appear clear to slightly opalescent and colourless.
Raztopina mora biti bistra do rahlo opalescentna in brezbarvna.
The solution will be clear to slightly opalescent and colourless.
Raztopina mora biti bistra do rahlo opalescentna in brezbarvna.
The solvent ampoule contains 5 ml water for injections.
Ampula z vehiklom vsebuje vodo za injekcije.
The solvent ampoule contains water for injections and sodium chloride.
Ampula z vehiklom vsebuje vodo za injekcije in natrijev klorid.
The solvent contains 35.4% w/w ethanol and polysorbate 80.
Raztopina vsebuje 35,4% etanola in polisorbata 80.
The solvent contains an ‘adjuvant’ (a compound containing oil) to enhance the immune response.
Emulzija vsebuje tudi „adjuvans“ (spojino, ki vsebuje olje) za povečanje imunskega odziva.
The solvent contains an ‘adjuvant’ (a compound containing oil) to enhance the immune response.
Emulzija vsebuje tudi „adjuvans“ (spojino, ki vsebuje olje) za spodbujanje imunskega odziva.
The solvent contains an ‘adjuvant’ (a compound containing oil) to enhance the immune response.
Vehikel vsebuje tudi „adjuvans“ (spojino, ki vsebuje olje) za povečanje imunskega odziva.
The solvent contains an ‘adjuvant’ (a compound containing oil) to enhance the immune response.
Vehikel vsebuje „adjuvans“ (sestavino, ki vsebuje olje) za okrepitev imunskega odziva.
The solvent contains calcium chloride dihydrate, sodium chloride and water for injections.
Vehikel vsebuje kalcijev klorid dihidrat, natrijev klorid in vodo za injekcije.
The solvent contains small amounts of ethanol (alcohol), less than 100 mg per dose.
Topilo vsebuje majhne količine etanola (alkohol), manj kot 100 g na odmerek.
The solvent contains sodium chloride and water for injections.
Vehikel vsebuje natrijev klorid in vodo za injekcije.
The solvent contains water for injections.
Vehikel vsebuje vodo za injekcije.
The solvent for Betaferon is provided in a 1.2 ml pre-filled syringe and contains 1.2 ml sodium chloride solution 5.4 mg/ml (0.54% w/v).
Vehikel za zdravilo Betaferon je na voljo v 1,2-mililitrski napolnjeni brizgi in vsebuje 1,2 ml raztopine natrijevega klorida 5,4 mg/ml (0,54 % m/v).
The solvent for Docefrez is 35.4% w/w Ethanol in Polysorbate 80.
Raztopilo za docefrez je 35,4% etanola v polisorbatu 80.
The solvent for Docetaxel 20 mg vial is a 6 ml clear glass vial with a bromobutyl rubber stopper and a flip-off cap.
Vehikel za vialo z 20 mg docetaksela je 6 ml viala iz prozornega stekla z zaporko iz brombutilne gume in pokrovčkom Flip Off.
The solvent for Docetaxel 20 mg/0.72 ml vial is a 6 ml clear glass vial with a bromobutyl rubber stopper and a flip-off cap.
Vehikel za docetaksel 20 mg/0,72 ml vialo je 6 ml viala iz prozornega stekla z zaporko iz brombutilne gume in pokrovčkom Flip Off.
The solvent for Docetaxel 80 mg vial is a 15 ml clear glass vial with a bromobutyl rubber stopper and a flip-off cap.
Viala z 80 mg vehikla za docetaksel je 15 ml viala iz prozornega stekla z zaporko iz brombutilne gume in pokrovčkom Flip Off.
The solvent for Docetaxel 80 mg/2.88 ml vial is a 15 ml clear glass vial with a bromobutyl rubber stopper and a flip-off cap.
Vehikel za docetaksel 80 mg/2,88 ml vialo je 15 ml viala iz prozornega stekla z zaporko iz brombutilne gume in pokrovčkom Flip Off.
The solvent for Docetaxel composition is water for injections.
Sestava vehikla za docetaksel je voda za injekcije.
The solvent for TAXOTERE 20 mg/0.5 ml vial is a 7 ml clear glass vial with a transparent colourless flip-off cap.
Viala z vehiklom za zdravilo TAXOTERE 20 mg/0,5 ml je 7-ml steklena viala iz prozornega stekla s prosojno, brezbarvno dvižno zaporko.
The solvent for TAXOTERE 80 mg/2 ml vial is a 15 ml clear glass vial with a transparent colourless flip-off cap.
Viala z vehiklom za zdravilo TAXOTERE 80 mg/2 ml je 15-ml steklena viala iz prozornega stekla s prosojno, brezbarvno dvižno zaporko.
The solvent for TAXOTERE composition is a 13% w/w solution of ethanol 95% in water for injections.
Vehikel za zdravilo TAXOTERE sestavlja 13 % (m/m) raztopina 95 % etanola v vodi za injekcije.
The solvent in Advocate may stain or damage certain materials including leather, fabrics, plastics and finished surfaces, so contact between the product and such surfaces should be avoided.
Vehikel v zdravilu Advocate lahko pusti madeže na nekaterih materialih, kot so usnje, tkanine, plastika in lakirane površine, oziroma jih poškoduje, zato preprečite stik zdravila s tovrstnimi površinami.
The solvent in Advocate may stain or damage certain materials including leather, fabrics, plastics and finished surfaces.
Topilo v zdravilu Advocate lahko pusti madeže na usnju, tkaninah, plastiki in lakiranih površinah ali jih poškoduje.
The solvent in Advocate may stain or damage certain materials including leather, fabrics, plastics and finished surfaces.
Topilo v zdravilu Advocate lahko pusti madeže na usnju, tkaninah, plastiki in lakiranih površinah.
The solvent in Prac-tic may stain certain materials including leather, fabrics, plastics and finished surfaces.
Topilo v zdravilu Prac-tic lahko pusti madeže na nekaterih materialih, vključno z usnjem, tkaninami, plastiko in lakiranimi površinami.
The solvent in this product may stain certain materials including painted, varnished or other household surfaces or furnishings.
Vehikel v tem zdravilu lahko na določenih materialih, vključno s pobarvanimi, lakiranimi ali drugimi gospodinjskimi površinami ali oblogami, pusti madež.
The solvent ingredients are carmellose sodium, mannitol, polysorbate 80, water for injections, hydrochloric acid and sodium hydroxide.
Pomožne snovi vehikla so natrijev karmelozat, manitol, polisorbat 80, voda za injekcije, klorovodikova kislina, natrijev hidroksid.
The solvent is 1 ml sterilised water for injections.
Vehikel je 1 ml sterilizirane vode za injekcije.
The solvent is a clear colourless liquid in a glass vial.
Vehikel je bistra brezbarvna tekočina v stekleni viali.
The solvent is a clear red solution.
Topilo je bistra rdeča raztopina.
The solvent is a clear, colourless fluid.
Vehikel je bistra, brezbarvna tekočina.
The solvent is a sodium chloride buffer.
Vehikel je 9 mg/ml (0,9 %) raztopina natrijevega klorida.
The solvent is sterile water for injection.
Vehikel je sterilna voda za injekcije.
The solvent is water for injection.
Vehikel je voda za injekcije.
The solvent is water for injections and is provided in a pre-filled glass syringe.
Vehikel je voda za injekcije in se nahaja v napolnjeni stekleni injekcijski brizgi.
The solvent is water for injections.
Topilo je voda za injekcije.
The solvent must be clear, red coloured, without sediment and at room temperature (15–25 °C) at the time of mixing
V času mešanja mora biti vehikel bister, rdeče obarvan, brez sedimenta in pri sobni temperaturi (15–25 °C).
The solvent must be clear, red coloured, without sediment and at room temperature (15–25 °C) at the time of mixing.
V času mešanja mora biti vehikel bister, rdeče obarvan, brez sedimenta in na sobni temperaturi (15–25 °C).
The solvent pre-filled syringe provided should be used for reconstitution only.
Priložen vehikel v napolnjeni injekcijski brizgi se sme uporabljati samo za rekonstitucijo.
The solvent should be emptied into the vial slowly to avoid the possibility of a foam forming.
Vehikel počasi izpraznite v vialo, da se izognete penjenju, ki naredi zdravilo neuporabno.
The solvent vial contains water for injections.
Viala z vehiklom vsebuje vodo za injekcije.
The solvent vial for Docefrez 20 mg is a 1 ml colourless type 1 tubular glass vial with 20 mm grey bromobutyl rubber stopper sealed with 20 mm dark blue flip-off aluminium seal.
Viala vehikla za Docefrez 20 mg je brezbarvnega cevastega stekla tipa 1 z 20 mm omniflex plus sivim brombutilnim gumijasto zaporko, zastesnjenim z 20 mm temnomodrim dvižnim aluminijastim tesnilom
The solvent vial for Docefrez 80 mg is a 5 ml colourless type 1 tubular glass vial with 20 mm grey bromobutyl rubber stopper sealed with 20 mm brown flip-off aluminium seal.
Viala vehikla za Docefrez 80 mg je brezbarvnega cevastega stekla tipa 1 z 20 mm omniflex plus sivim brombutilnim gumijasto zaporko, zastesnjenim z 20 mm temnomodrim dvižnim aluminijastim tesnilom.
The solvent will be pulled into the powder vial by the vacuum contained within it.
Vehikel bo stekel v vialo s praškom zaradi vakuuma v viali z zdravilom.
The sonidegib plasma concentration-QTc analysis showed that the upper bound of one-sided 95% confidence interval for QTc increase was below 5 msec at steady-state Cmax for 800 mg daily doses, which provide
Analiza povezave med koncentracijo sonidegiba v plazmi in trajanjem intervala QTc je pokazala, da je bila zgornja meja enostranskega 95-odstotnega intervala zaupanja za podaljšanje intervala QTc manj kot
The sound of the motor will stop once Herceptin has been fully injected.
Ko se bo zdravilo Herceptin v celoti injiciralo, bo zvok motorja utihnil.
The SPC of the co-administered PI should be reviewed for specific dosing information in this patient population.
Za specifične informacije o odmerjanju pri tej populaciji bolnikov glejte povzetek glavnih značilnosti za sočasno uporabljeni zaviralec proteaz.
The special warnings and precautions relevant to abacavir and lamivudine are included in this section.
V to poglavje so vključena posebna opozorila in previdnostni ukrepi, ki se nanašajo na abakavir in lamivudin.
The special warnings and precautions relevant to abacavir, lamivudine and zidovudine are included in this section.
V to poglavje so vključena posebna opozorila in previdnostni ukrepi, ki se nanašajo na abakavir, lamivudin in zidovudin.
The species most frequently involved in causing human infections include C. albicans, C. parapsilosis, C.tropicalis, C. glabrata andC. krusei, all of which usually exhibit minimal inhibitory concentration (MICs) of less than 1 mg/L for voriconazole.
Vrste, ki so najpogosteje vpletene pri povzročanju okužb pri ljudeh, so C. albicans, C. parapsilosis, C. tropicalis, C. glabrata in C. krusei, pri čemer pri vseh naštetih minimalna inhibitorna koncentracija (MIK) za vorikonazol običajno znaša manj kot 1 mg/L.
The specific activity of ALPROLIX is 55-84 IU/mg protein.
Specifična aktivnost zdravila ALPROLIX je 55–84 i.e./mg beljakovine.
The specific activity of Nonafact is at least 200 IU/mg protein.
Specifična aktivnost zdravila Nonafact je vsaj 200 i.e./mg beljakovin.
The specific activity of RIXUBIS is approximately 200-390 IU/mg protein.
Specifična aktivnost zdravila RIXUBIS je približno 200–390 i.e./mg beljakovin.
The specific activity of the medicinal product at ART is indicated on the label and always greater than 3000 GBq/mg.
Specifična aktivnost zdravila v času ART je navedena na ovojnini in je vedno višja od 3 000 GBq/mg.
The specific frequency cannnot be estimated from available data (frequency not known).
Specifične pogostnosti ni mogoče oceniti iz razpoložljivih podatkov (neznana pogostnost).
The specific frequency cannot be estimated from available data (frequency not know).
Specifične pogostnosti ni mogoče oceniti iz razpoložljivih podatkov (neznana pogostnost).
The specific mechanism of action of hydroxycarbamide is not fully understood.
Specifični mehanizem delovanja hidroksikarbamida je zaenkrat še nejasen.
The specific mechanism of action of hydroxycarbamide is not fully understood.
Specifični mehanizem učinkovanja hidroksikarbamida je zaenkrat še nejasen.
The specific α2 – adrenoceptor antagonist, atipamezole, which is approved for use in animals, has been used in humans only experimentally to antagonize dexmedetomidine-induced effects.
Specifičen antagonist α2 adrenoreceptorjev, odobren za uporabo pri malih živalih, je bil pri človeku uporabljen kot antagonist učinkov deksmedetomidina samo poskusno.
The specific α2 – adrenoceptor antagonist, atipamezole, which is approved for use in animals, has been used in humans only experimentally to antagonize dexmedetomidine-induced effects.
Specifičen antagonist α2 adrenoreceptorjev, odobren za uporabo pri živalih, je bil pri človeku kot antagonist učinkov deksmedetomidina uporabljen samo poskusno.
The specific α2 – adrenoceptor antagonist, atipamezole, which is approved for use in animals, has been used in humans only experimentally to antagonize dexmedetomidine-induced effects.
Specifičen antagonist α2 adrenoreceptorjev, odobren za uporabo pri živalih, je bil pri človeku uporabljen kot antagonist učinkov deksmedetomidina samo poskusno.
The specific α2- adrenoceptor antagonist, atipamezole, which is approved for use in animals, has been used in humans only experimentally to antagonize dexmedetomidine-induced effects.
Specifičen antagonist α2 adrenoreceptorjev, odobren za uporabo pri malih živalih, je bil pri človeku uporabljen kot antagonist učinkov deksmedetomidina samo poskusno.
The specification of breath analysis parameters like linearity, stability (reference gas precision), and precision of measurement are fundamental for the accuracy of the system.
Podroben opis parametrov analize zraka – linearnost, stabilnost (natančnost referenčnega plina), ter natančnost meritev – sta bistvena pogoja za točnost sistema.
The specification of breath analysis parameters like linearity, stability (reference gas precision), and precision of measurement are fundamental for the accuracy of the system.
Podroben opis parametrov analize zraka – linearnost, stabilnost (natančnost referenčnega plina), ter natančnost meritev – sta bistvena pogoja za točnost testnih rezultatov.
The specificity estimates were all above 90% with corresponding lower confidence limits ranging from 85% to 90%.
Ocene specifičnosti so vse bile nad 90 % z ustreznimi spodnjimi mejami zaupanja od 85 % do 90 %.
The specificity of eculizumab for C5 in human serum was evaluated in two in vitro studies.
Specifičnost ekulizumaba za C5 v humanem serumu so preučevali v okviru dveh študij in vitro.
The speed of administration should be based on the patient’s comfort, but should not be faster than 2ml/min maximum rate of infusion.
Hitrost injiciranja naj bo prilagojena počutju bolnika (največja hitrost injiciranja je 2 ml/min).
The speed of automatic injection is at least 2,500 eggs per hour, therefore solvent presentation of at least or more than 400 ml is recommended to prime and inject for longer than 10 minutes.
Hitrost avtomatskega injiciranja je vsaj 2.500 jajc na uro, zato se za injiciranje dlje kot 10 minut priporoča uporaba najmanj 400 ml topila za injiciranje.
The SPID for PecFent-treated episodes was also significantly different to placebo at 10 15, 45 and 60 minutes after administration.
SPID epizod, zdravljenih z zdravilom PecFent, se je tudi značilno razlikoval od placeba 10, 15, 45 in 60 minut po uporabi.
The spleen is an organ that is involved in the destruction of platelets.
Vranica je majhen organ, ki se nahaja za želodcem in sodeluje pri odstranjevanju trombocitov iz krvi.
The sponge is left in the body, where it dissolves and disappears completely.
Gobica ostane v telesu, kjer se raztopi in popolnoma izgine.
The sponge is white and it is presented in a plastic blister.
Goba je bela in je dobavljena v plastičnem pretisnem omotu.
The spot on pipette is composed of a bright yellow polypropylene shell, with a pale yellow aluminium foil back coated with a polyethylene terephthalate film.
Merilna kapalka je sestavljena iz svetlo rumenega polipropilenskega telesa z bledo rumeno aluminijevo folijo, prekrito s filmom iz polietilen tereftalata.
The spray should be administered into the dog’s mouth, with the mist being directed to the back and towards the gums and/or inner cheek.
Pršilo se nanese v gobec psa, pršenje pa se usmeri nazaj in proti dlesnim in/ali notranjim ličnicam.
The spraying distance should be between 30 and 80 cm above the animals in order to ensure an even distribution and the recommended droplet size is greater than 100 µm.
Razprševanje mora potekati med 30 do 80 cm nad živalmi, da bo razporeditev čim enakomernejša, priporočljiva velikost kapljic pa je več kot 100 µm.
the stage of your breast cancer how well your body responds to the medicine.
topnje razvitosti vašega raka; kako dobro se telo odziva na zdravilo.
The standard and reduced Teysuno and cisplatin doses and calculations according to body surface area (BSA) for doses of Teysuno given in combination with cisplatin are provided in Table 1 and Table 2, respectively.
Standardni in zmanjšani odmerki zdravila Teysuno in cisplatina ter izračuni glede na telesno površino (BSA – »body surface area«) za odmerke zdravila Teysuno, ki se predpiše v kombinaciji s cisplatinom, so navedeni v Preglednici 1 in Preglednici 2, in sicer v tem zaporedju.
The standard dose for adults is 100 or 200 mg, once or twice a day.
Običajni odmerek za odrasle je 100 ali 200 mg enkrat ali dvakrat na dan.
The standard dose for tablets is 3 mg pradofloxacin per kilogram body weight once a day.
Običajni odmerek tablet je 3 mg pradofloksacina na kilogram telesne mase enkrat na dan.
The standard dose is 800 mg every eight hours.
Standardni odmerek je 800 mg vsakih osem ur.
The standard dose of Clopidogrel Krka is one 75 mg tablet once a day, taken with or without food.
Običajni odmerek zdravila Clopidogrel Krka je ena 75-miligramska tableta enkrat na dan, ki se vzame s hrano ali brez nje.
The standard dose of Clopidogrel Qualimed is one 75 mg tablet once a day, taken with or without food.
Običajni odmerek zdravila Clopidogrel Qualimed je ena 75-miligramska tableta enkrat na dan, ki se vzame s hrano ali brez nje.
The standard dose of Clopidogrel TAD is one 75 mg tablet once a day, taken with or without food.
Običajni odmerek zdravila Clopidogrel TAD je ena 75-miligramska tableta enkrat na dan, ki se vzame s hrano ali brez nje.
The standard dose of Clopidogrel Teva Generics B.V. is one 75-mg tablet once a day, taken with or without food.
Običajni odmerek zdravila Clopidogrel Teva Generics B.V. je ena 75-miligramska tableta enkrat na dan, ki se vzame s hrano ali brez nje.
The standard dose of Clopidogrel Teva Pharma B.V. is one 75-mg tablet once a day, taken with or without food.
Običajni odmerek zdravila Clopidogrel Teva Pharma B.V. je ena 75-miligramska tableta enkrat na dan, ki se vzame s hrano ali brez nje.
The standard dose of Clopidogrel Teva Pharma is one 75-mg tablet once a day.
Običajni odmerek zdravila Clopidogrel Teva Pharma je ena 75-miligramska tableta enkrat na dan.
The standard dose of Cystadane for patients aged over 10 years is 6 g a day, divided into two equal doses.
Standardni odmerek zdravila Cystadane za bolnike, starejše od 10 let, je 6 g na dan, razdeljen v dva enaka odmerka.
The standard dose of Iscover is one 75-mg tablet once a day.
Priporočeni odmerek zdravila Iscover je ena 75–miligramska tableta enkrat dnevno.
The standard dose of Plavix is one 75-mg tablet once a day.
Priporočeni odmerek zdravila Plavix je ena 75–miligramska tableta enkrat dnevno.